Label Changes for:
Alimta (pemetrexed for injection) for intravenous use, 100 mg and 500 mg vials
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
- These reactions occurred with Alimta when used as a single-agent and in combination therapies.
- Blood and Lymphatic System — immune-mediated hemolytic anemia